Nitto Avecia Bolsters its Commitment to Oligonucleotide Clients in Global Markets with the Addition of Specialist Juergen Mueller
Cincinnati, Ohio (PRWEB) March 26, 2014 -- Nitto Denko Avecia Inc. has added a new Director of Business Development, Dr. Juergen Mueller, to focus on its global oligonucleotide clients. This move strengthens Nitto Avecia’s commitment to expand its client base, particularly in Europe, after its strong 2013 performance and anticipated additional growth this year.
Dr. Mueller’s expertise and background is in the pharmaceutical, animal health and nutrition fields, as well as the biotech sector. He has extensive international experience in the life science industry, where he has held senior positions in Business Development, Sales and Marketing, Licensing and Project Management with companies such as Sigma-Aldrich and Neuland Laboratories.
In his new role Dr. Mueller will focus on the continued development of Nitto Avecia’s oligonucleotide unit for European clients. After working in overseas markets with several international companies, he has a strong familiarity with clients in Europe. “I am particularly excited to be part of a company that is at the forefront of efforts to advance and manufacture the pipeline of next-generation oligo therapeutics. It’s great to get the opportunity to become part of Nitto Avecia’s team and I am very keen to contribute by expanding the company's client base in Europe,” says Dr. Mueller.
Dr. Mueller also says he believes that the combination of Nitto Avecia’s highly qualified and motivated personnel, together with its strong scientific platform and technical expertise, hold a great deal of promise for the future success of clients’ projects.
Emily Johnson, Nitto Avecia Inc., http://www.avecia.com, +1 (513) 679-3031, [email protected]
Share this article